NAT2: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior
Xiyun Chen1, Guang Yang1, Cheng Lou1
1Department of Oncology, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Background:
Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer typically diagnosed at advanced stages, limiting treatment options and reducing survival rates. Targeted therapy presents a promising strategy to improve outcomes. This study aims to identify novel molecular biomarkers influencing ICC development and explore their roles in tumor progression.
Methods:
Data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were analyzed using weighted gene co-expression network analysis (WGCNA) to identify genes related to tumor metastasis and recurrence. Survival analysis and gene set enrichment analysis (GSEA) assessed the relationship between gene expression and survival, as well as associated signaling pathways. Cellular experiments, including small interfering RNA (siRNA) knockdown, cell viability assays, Transwell migration assays, and flow cytometry, were performed.
Results:
The Kaplan-Meier analysis showed that ICC patients with high N-acetyltransferase 2 (NAT2) expression had significantly shorter survival times than those with low expression (P < .001). Gene set enrichment analysis revealed enrichment of MYC and MTORC1 pathways, linked to tumor proliferation, and E2F and G2M pathways, which regulate the cell cycle, in high NAT2 expression samples (P < .01). The NAT2 knockdown reduced RBE cell proliferation (P < .001) and increased late apoptosis (P < .001). Immunofluorescence analysis showed increased Bax and Caspase-3 expression and decreased BCL-2 expression (P < .05), supporting NAT2's role in regulating ICC cell apoptosis.
Conclusion:
NAT2, a novel therapeutic target, holds significant potential to improve the prognosis of ICC patients.
Insights
High N-acetyltransferase 2 (NAT2) expression correlates with poor survival in intrahepatic cholangiocarcinoma (ICC). Targeting NAT2 may improve prognosis for ICC patients, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer often diagnosed late, limiting treatment and survival.
- Targeted therapies offer a promising avenue for improving ICC patient outcomes.
- Identifying novel molecular biomarkers is crucial for understanding ICC development and progression.
Purpose of the Study:
- To identify novel molecular biomarkers for intrahepatic cholangiocarcinoma (ICC).
- To investigate the role of identified biomarkers in ICC tumor progression and patient prognosis.
- To explore potential therapeutic targets for ICC.
Main Methods:
- Weighted gene co-expression network analysis (WGCNA) on TCGA and GEO data to identify metastasis/recurrence-related genes.
- Kaplan-Meier survival analysis and gene set enrichment analysis (GSEA) to assess gene-expression-survival relationships and pathways.
- In vitro experiments including siRNA knockdown, cell viability, migration assays, and flow cytometry to validate findings.
Main Results:
- High N-acetyltransferase 2 (NAT2) expression was significantly associated with shorter survival in ICC patients (P < .001).
- NAT2 expression correlated with MYC, MTORC1, E2F, and G2M pathways involved in proliferation and cell cycle regulation (P < .01).
- NAT2 knockdown reduced ICC cell proliferation and increased apoptosis, affecting Bax, Caspase-3, and BCL-2 expression.
Conclusions:
- N-acetyltransferase 2 (NAT2) is a novel molecular biomarker in intrahepatic cholangiocarcinoma (ICC).
- NAT2 plays a significant role in regulating ICC cell proliferation and apoptosis.
- Targeting NAT2 presents a promising therapeutic strategy to improve ICC patient prognosis.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
